KCT0001539
Active, not recruiting
未知
Phase I Study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of HM95573 in solid tumors
Hanmi Pharm0 sites72 target enrollmentTBD
ConditionsNeoplasms
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Hanmi Pharm
- Enrollment
- 72
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients must be 19 years of age or older
- •2\. Subjects who have provided voluntary consent to participate in the study, and signed the written consent document.
- •3\. Estimated life expectancy of at least 12 weeks
- •4\. Histologically or cytologically confirmed advanced solid tumor
Exclusion Criteria
- •1\.Symptomatic or uncontrolled central nervous system metastases
- •2\. Patients who are unable to take tablets orally or have a clinically significant gastrointestinal disorder, which may interfere with administration, metabolism and absorption of the investigational drug.
- •3\. Patients who, in the investigator’s opinion, are not suitable for the study for any other reason.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in men with biochemical recurrence of prostate cancerbiochemical recurrence after curativelyintended therapy for localized PCDRKS00031816niversitätsklinikum Tübingen38
Completed
Not Applicable
Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics and pharmacodynamics of monoclonal antibody TB31F in healthy malaria-naïve adults in the NetherlandsNL-OMON50099Radboud Universitair Medisch Centrum25
Completed
Phase 1
Safety, tolerability and pharmacokinetics study of WCK 2349 (in single doses) in healthy male volunteer.CTRI/2009/091/000377Wockhardt Ltd84
Completed
Not Applicable
A Phase I study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of HTX-011-19 (a long acting formulation of 5% bupivacaine and 0.15% meloxicam) and HTX-011-49 (a long acting formulation of 2.5% bupivacaine and 0.075% meloxicam) after subcutaneous administration in healthy subjects.post-operative painanalgesicsNL-OMON41936Heron Therapeutics, Inc.46
Completed
Phase 1
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisACTRN12614001199606TB4 Sweden AB30